Nexus (NXS.V) has been in Burkina Faso for years. With a new acquisition announced just yesterday, the company now controls over 750-square kilometers of highly prospective terrain in the prolific gold producing West African nation.
If you’ve had your eye off the biotech sector recently because it doesn’t directly involve gold or cannabis, you’re missing out on one of the better casinos out there. For the high risk, high reward investor, nothing is quite like the thrill of correctly picking when a long, drawn out, US Food and Drug Administration process of approving a new drug finally gets over the line.
Resverlogix (RVX.T), Sirona Biochem (SBM.V), Sernova (SVA.V): 3 Canadian biotechs tackle a $330 billion health crisis
A Harvard University Study calculates the economic burden from diabetes at about $1.3 trillion, or 1.8% of global GDP.
BC-based battery metals developer Nano One Materials (NNO.V) has long been a favourite at Equity.Guru – in fact, it’s been the stock we’ve held longest out of all the companies we hold. That’s been a wise decision, as we’ve watched it roll from $0.50 a few years back to $1.15 more recently, but the one beef we’ve long had with the Nano crowd is, they’re very operation-focused and can, at times, forget about the stock for extended periods while they continue to prove out their tech and advance some large scale partnerships.
If you guys can't spot a bubble by now, what day in February did you start trading exactly? Tesla (TSLA.Q) stock has been on a nutty run lately, climbing from the $200 range in October to $969 yesterday. Or, rather '..to $969, 15 minutes before the end of trading today.'